Vir Biotechnology (VIR) Assets Average (2019 - 2026)

Vir Biotechnology has reported Assets Average for 8 years, with the latest figure at $1.0 billion in Q1 2026.

• Quarterly Assets Average fell 25.06% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 25.06% YoY) and the FY2025 annual result came in at $1.2 billion, down 27.62% from the prior year.
• Assets Average steadied at $1.0 billion in Q1 2026 per VIR's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Assets Average peaked at $2.8 billion in Q2 2022 and troughed at $1.0 billion in Q4 2025.
• A 5-year average of $1.9 billion and a median of $1.9 billion in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2024: Assets Average soared 151.06% in 2022, then sank 32.1% in 2024.
• Over 5 years, Assets Average stood at $2.7 billion in 2022, then dropped by 27.9% to $2.0 billion in 2023, then fell by 26.91% to $1.4 billion in 2024, then sank by 30.2% to $1.0 billion in 2025, then climbed by 0.3% to $1.0 billion in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $1.0 billion, $1.0 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.